Marjan Yaghmaie1, Cecilia Cs Yeung2,3. 1. Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran. marjix58@gmail.com. 2. Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA. 3. Department of Pathology, University of Washington, Seattle, WA, USA.
Abstract
PURPOSE OF REVIEW: Chronic myeloid leukemia (CML) patients with constitutive activity of BCR-ABL1 oncoprotein frequently derive significant clinical benefits from tyrosine kinase inhibitors (TKIs). Point mutations in the ABL1 kinase domain (KD) are an important mechanism of TKI resistance in CML. In this review, we present molecular mechanisms of TKI resistance paying particular attention to drug resistance which allows for a survival advantage in CML. RECENT FINDINGS: Sensitive disease monitoring is a required standard of care for management of CML. Screening of these mutations fail to explain 20-40% of resistant cases where activation of different survival pathways must be the main reason for resistance. Eliminating TKI resistance appears to be the most successful therapeutic way to decrease leukemic disease burden and potentiate cure. Advances on novel strategies for identifying and confronting drug resistance are rapidly altering management of CML that are resistant to TKI and expanding the landscape of available therapies.
PURPOSE OF REVIEW: Chronic myeloid leukemia (CML) patients with constitutive activity of BCR-ABL1 oncoprotein frequently derive significant clinical benefits from tyrosine kinase inhibitors (TKIs). Point mutations in the ABL1 kinase domain (KD) are an important mechanism of TKI resistance in CML. In this review, we present molecular mechanisms of TKI resistance paying particular attention to drug resistance which allows for a survival advantage in CML. RECENT FINDINGS: Sensitive disease monitoring is a required standard of care for management of CML. Screening of these mutations fail to explain 20-40% of resistant cases where activation of different survival pathways must be the main reason for resistance. Eliminating TKI resistance appears to be the most successful therapeutic way to decrease leukemic disease burden and potentiate cure. Advances on novel strategies for identifying and confronting drug resistance are rapidly altering management of CML that are resistant to TKI and expanding the landscape of available therapies.
Authors: Matthew S Zabriskie; Christopher A Eide; Srinivas K Tantravahi; Nadeem A Vellore; Johanna Estrada; Franck E Nicolini; Hanna J Khoury; Richard A Larson; Marina Konopleva; Jorge E Cortes; Hagop Kantarjian; Elias J Jabbour; Steven M Kornblau; Jeffrey H Lipton; Delphine Rea; Leif Stenke; Gisela Barbany; Thoralf Lange; Juan-Carlos Hernández-Boluda; Gert J Ossenkoppele; Richard D Press; Charles Chuah; Stuart L Goldberg; Meir Wetzler; Francois-Xavier Mahon; Gabriel Etienne; Michele Baccarani; Simona Soverini; Gianantonio Rosti; Philippe Rousselot; Ran Friedman; Marie Deininger; Kimberly R Reynolds; William L Heaton; Anna M Eiring; Anthony D Pomicter; Jamshid S Khorashad; Todd W Kelley; Riccardo Baron; Brian J Druker; Michael W Deininger; Thomas O'Hare Journal: Cancer Cell Date: 2014-08-14 Impact factor: 31.743
Authors: Jamshid S Khorashad; Todd W Kelley; Philippe Szankasi; Clinton C Mason; Simona Soverini; Lauren T Adrian; Christopher A Eide; Matthew S Zabriskie; Thoralf Lange; Johanna C Estrada; Anthony D Pomicter; Anna M Eiring; Ira L Kraft; David J Anderson; Zhimin Gu; Mary Alikian; Alistair G Reid; Letizia Foroni; David Marin; Brian J Druker; Thomas O'Hare; Michael W Deininger Journal: Blood Date: 2012-12-05 Impact factor: 22.113
Authors: Susan Branford; David T Yeung; David M Ross; Jodi A Prime; Chani R Field; Haley K Altamura; Alexandra L Yeoman; Jasmina Georgievski; Bronte A Jamison; Stuart Phillis; Brad Sullivan; Nancy E Briggs; Mark Hertzberg; John F Seymour; John Reynolds; Timothy P Hughes Journal: Blood Date: 2013-03-20 Impact factor: 22.113
Authors: Yuhong Lu; Yanfeng Liu; Sebastian Oeck; Gary J Zhang; Alexander Schramm; Peter M Glazer Journal: Cancer Res Date: 2020-09-01 Impact factor: 12.701